Camurus
673,5 SEK -1,97%7 investorer følger denne virksomhed
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Omsætning
-
EBIT %
-
P/E
86,57
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
CAMX
Daglig lav / høj pris
673,5 / 696
SEK
Markedsværdi
39,49 mia. SEK
Aktieomsætning
39,91 mio. SEK
Volumen
58 t
Seneste videoer
Finanskalender
Delårsrapport
07.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Sandberg Development AB | 35,0 % | 35,2 % |
Fjärde AP-fonden | 4,5 % | 4,5 % |
JP Morgan Chase Bank | 3,6 % | 3,6 % |
Swedbank Robur Fonder | 3,3 % | 3,4 % |
Avanza Pension | 2,9 % | 3,0 % |
Fredrik Tiberg | 2,8 % | 2,8 % |
State Street Bank and Trust | 2,6 % | 2,6 % |
Handelsbanken Fonder | 2,6 % | 2,6 % |
The Bank of New York Mellon SA/NV | 1,5 % | 1,5 % |
Norges Bank | 1,2 % | 1,2 % |
ViserAlle indholdstyper
Camurus AB: Camurus' Interim Report Second Quarter 2024
Camurus AB: Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools